Clade Therapeutics is a cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines. Clade is combining the expertise with its proprietary immune “cloaking” of human iPSCs and their adult derivatives, novel universal targeting, and cellular enhancements to enable the development of true “off-the-shelf” cell therapies.

Clade is a leading innovator in developing engineerable, off-the-shelf, scalable, and consistent cell medicines.